Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score -20.02
- Piotroski Score 3.00
- Grade Overweight
- Symbol (BIVI)
- Company BioVie Inc.
- Price $3.36
- Changes Percentage (-4.42%)
- Change -$0.16
- Day Low $3.32
- Day High $3.62
- Year High $58.20
BioVie Inc., a clinical stage biotechnology company, engages in the discovery, development, and commercialization of drugs therapies in the United States. Its products in pipeline include BIV201, which completed Phase IIa clinical trial for the treatment of ascites due to chronic liver cirrhosis; and NE3107, which is in Phase III clinical trial for the treatment of patients with mild to moderate Alzheimer's disease and Phase I clinical trial for the treatment of Parkinson's disease. The company is also developing NE3107, which is in pre-clinical stage for the treatment of multiple myeloma and prostate cancer. The company was formerly known as NanoAntibiotics, Inc. and changed its name to BioVie Inc. in July 2016. BioVie Inc. was incorporated in 2013 and is based in Carson City, Nevada.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 02/11/2025
- Fiscal Year End N/A
- Average Stock Price Target $0.00
- High Stock Price Target $0.00
- Low Stock Price Target $0.00
- Potential Upside/Downside N/A
- Consensus Rating Sell
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$0.93
- Trailing P/E Ratio -0.46
- Forward P/E Ratio -0.46
- P/E Growth -0.46
- Net Income $-32,120,533
Income Statement
Quarterly
Annual
Latest News of BIVI
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
BioVie Inc. (BIVI) Stock Price, News, Quote & History - Yahoo Finance
BioVie's terlipressin liquid formulation patent approved in Japan, securing its place in the US, India, and Chile. The stable formulation benefits patients with cirrhosis and ascites, providing a sign...
By Yahoo! Finance | 1 month ago -
Individual investors invested in BioVie Inc. (NASDAQ:BIVI) copped the brunt of last week's US$55m market cap decline
Individual investors own a significant portion of BioVie Inc. (NASDAQ:BIVI) with 49% ownership, experiencing high losses as market cap fell. Institutional investors and insiders also hold shares, with...
By Yahoo! Finance | 3 months ago
